Human Genome's Risk-Management Math
Human Genome Sciences believes its lead in genomics--it claims to have nearly all human genes in its database--is already letting it beat the biotech odds in the clinic by allowing it to pick better proteins to develop and then follow them up with a virtually inexhaustible source of new candidates. Skeptics don't like the company's arithmetic.
You may also be interested in...
Confidence in the vaccine has slipped in the US, regardless of political affiliation.
Can "real world evidence" drive consumer health innovation? HBW Insight speaks to Orbital Research’s Chris Bunniss about RWE’s potential for the OTC industry.
Italy's Chiesi is looking to take a slice of Poland's consumer healthcare market by acquiring infant supplements specialist Smart Pharma.